Dysregulation of microRNAs and Centromere Protein Genes in Prostate Cancer and Metastatic Progression
Urology Research and Practice · 02.04.2026 · 52 · 1-8
DOI: 10.5152/tud.2026.26143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urology Research and Practice, online erschienen am 02.04.2026. Verfasst von Makbule Nihan Somuncu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Accurate prediction of disease progression and metastatic potential remains a major challenge in prostate cancer management. This study aimed to evaluate the expression profiles of selected microRNAs (miRNAs) and cell cycle–related genes as centromere protein genes (CENPs) in prostate cancer and to explore their potential clinical relevance in distinguishing metastatic disease.
Methods
Formalin-fixed paraffin-embedded prostate tissue samples from patients with benign prostatic hyperplasia, localized prostate cancer, and metastatic prostate cancer were analyzed. Quantitative real-time polymerase chain reaction (PCR) (qRTPCR) was used to assess the expression of miRNAs targeted CENPs as well as CENPA, CENPC, HJURP, and AURKB. Expression patterns were further validated in the metastatic prostate cancer cell line PC3. Relative expression levels were calculated using the 2−ΔΔCt (cycle threshold) method.
Results
Expression analysis of selected miRNAs revealed a significant upregulation of hsa-miR-4755-5p in the metastatic PCa (P = .027), despite no significant differences in fold change. Additionally, hsa-miR-5680 showed a significantly higher fold change in the metastatic group compared to controls (P = .034). Although not statistically significant (P > .05), hsa-miR-5688, hsa-miR-20a-5p, and hsa-miR-4500 demonstrated a consistent trend toward downregulation, as indicated by lower ΔΔCt values in both PCa and metastatic groups relative to controls. In PCa cell line CENPA, CENPC,and HJURP expression levels increased over time, whereas AURKB was downregulated.
Conclusion
The findings indicate that combined dysregulation of specific microRNAs and centromere-associated genes characterizes metastatic prostate cancer. This molecular signature may provide clinically relevant information for risk stratification and warrants further investigation as a potential adjunct to conventional prognostic markers in prostate cancer. Cite this article as: Somuncu MN, Karalezli I, Göger YE, et al. Dysregulation of microRNAs and centromere protein genes in prostate cancer and metastatic progression. Urol Res Pract., 52, 0143, doi:10.5152/tud.2026.26143.
Autor:innen und Institutionen
- Department of Medical Genetics, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.
- Selçuk University, Vocational School of Health Services, Konya, Türkiye.
- Department of Urology, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.
- Sakarya University Faculty of Medicine, Sakarya, Türkiye.
- Department of Pathology, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.
- Department of Urology, Beyhekim State Hospital, Konya, Türkiye.
Zitieren
APA
Somuncu, M. N., Karalezli, İ., Göger, Y. E., Zamani, A. G., Yıldırım, M. S., Deveci, A., Avunduk, M. C., & Karalezli, G. (2026). Dysregulation of microRNAs and Centromere Protein Genes in Prostate Cancer and Metastatic Progression. Urology Research and Practice, 52, 1-8. https://doi.org/10.5152/tud.2026.26143
Vancouver
Somuncu MN, Karalezli İ, Göger YE, Zamani AG, Yıldırım MS, Deveci A, et al. Dysregulation of microRNAs and Centromere Protein Genes in Prostate Cancer and Metastatic Progression. Urology Research and Practice. 2026;52:1-8. doi:10.5152/tud.2026.26143
BibTeX
@article{Somuncu2026,
author = {Somuncu, Makbule Nihan and Karalezli, İlknur and Göger, Yunus Emre and Zamani, Ayşe Gül and Yıldırım, Mahmut Selman and Deveci, Asuman and Avunduk, Mustafa Cihat and Karalezli, Giray},
title = {Dysregulation of microRNAs and Centromere Protein Genes in Prostate Cancer and Metastatic Progression},
journal = {Urology Research and Practice},
year = {2026},
volume = {52},
pages = {1--8},
doi = {10.5152/tud.2026.26143}
}
EUVIMED